Download presentation
Presentation is loading. Please wait.
Published byNicholas Patrick Modified over 9 years ago
1
Plans for Diagnosis of Community Acquired Pneumonia
2
CAP Any of the ff: RR ≥30/min PR ≥125/min Temp ≥40 or ≤35°C Suspected aspiration Extrapulmonary evidence of sepsis Unstable comorbid conditions CXR: multilobar, pleural effusion, abscess, progression of lesion to 75% in 24 hours Low risk CAP Out-patient NO YES Any of the ff: 1.Shock or signs of hypoperfusion, hypotension, altered mental state, urine output <30ml/hr 2.PaO 2 50mmHg) at room air YES NO Moderate risk CAP In-patient High risk CAP ICU Philippine Community-Acquired Pneumonia (CAP) Guidelines 2004
3
Diagnosis Diagnosis is suspected on the basis of clinical presentation and is confirmed by chest x-ray
5
Chest x-ray almost always demonstrates some degree of infiltrate. In general, no specific findings distinguish one type of pneumonial infection from another, though: – multilobar infiltrates suggest S. pneumoniae or Legionella pneumophila infection – interstitial pneumonia suggests viral or mycoplasmal etiology.
6
Diagnostic plan CBC CXR Gram stain and culture of the sputum Sputum AFB smear to rule out active TB
7
Plans for Management of Community Acquired Pneumonia
8
MANAGEMENT OF CAP Fish D. Pneumonia. PSAP, Pharmacotherapy Self-Assessment Program. Kansas City, Mo.: American College of Clinical Pharmacy, 2002:202.
9
Management Empirical antibiotic administration – Azithromycin 500 mg IV q 24 h plus β-lactam IV (cefotaxime 1 to 2 g q 8 to 12 h; ceftriaxone 1 g q 24 h) – Macrolides – Antipneumococcal fluoroquinolone po or IV Improvement is manifested by decreased cough and dyspnea, defervescence, relief of chest pain, and decline in WBC count. Failure to improve should rise suspicion of: – an unusual organism – Resistance to antibiotic – Empyema – coinfection or superinfection with a 2nd infectious agent
10
Management Supportive care: – Fluids – Antipyretics Advise to refer back to DOTs with X-ray and sputum AFB results as outpatient
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.